Loading...
•
Sep 30, 2022
Guardant Health Q3 2022 Earnings Report
Reported a revenue increase of 24% year-over-year, driven by growth in clinical and biopharma testing volumes.
Key Takeaways
Guardant Health reported revenue of $117.4 million for the third quarter of 2022, a 24% increase compared to the same period in 2021. The growth was primarily driven by a 42% increase in clinical testing volume and a 40% increase in biopharma sample volume. The company also made progress on the ECLIPSE study and the Shield LDT screening test.
Revenue of $117.4 million for the third quarter of 2022, an increase of 24% over the corresponding period of 2021
Reported 32,400 tests to clinical customers and 6,750 tests to biopharmaceutical customers in the third quarter of 2022, representing an increase of 42% and 40%, respectively, over the third quarter of 2021
Expanded Guardant Reveal™ , the only tissue-free liquid biopsy test for detection of residual and recurrent disease, to include early-stage breast and lung cancers in addition to colorectal cancer
Received FDA approval for Guardant360® CDx liquid biopsy test as a companion diagnostic for ENHERTU® for treatment of non-small cell lung cancer patients with activating HER2 mutations
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health now expects full year 2022 revenue to be in the range of $440 million to $450 million, representing growth of 18% to 20% compared to full year 2021.